Dr Benjamin Shaw, CEO
Benjamin completed his undergraduate degree in Biological Sciences at the University of Oxford. He was then accepted onto the prestigious Wellcome Trust PhD Studentship for Developmental Biology at the University of Cambridge. He is now strengthening his business knowledge through active engagement with the Accelerate Programme at the Cambridge Judge Business School. This makes him an ideal candidate to communicate the science and the business to potential investors and buyers, in addition to his scientific role within the company.
Dr Gustavo Cerda-Moya, CTO and inventor
Gustavo completed his PhD at the University of Cambridge in the field of molecular biology. He then went on to do a successful Post-doc also at the University of Cambridge. Using his knowledge of molecular biology, he discovered a revolutionary method of detecting DNA. He now works full time for Swift Molecular Diagnostics.
Andrew Taylor, Non- Executive Director
Andy is a Big Four trained Chartered Accountant who has worked with privately owned UK businesses, one of the largest FTSE 100 companies and as CFO of a main market listed PLC.
Since 2011 Andy has been working as a portfolio FD supporting small and medium sized companies in Cambridge. He has provided numerous clients across diverse industries with varying levels of support, whether it be one-off assignments (such as fund raising, due diligence, forecasting and budgeting, and year ends) or the provision of full FD services on a part time basis.
Sam Hussain, Non-Executive Director
Sam is a former management consultant who is now working with early-stage startups. After graduating with a Masters in Engineering from Oxford, he spent three and a half years as a consultant at Oliver Wyman. While he was there, he worked on strategy projects including writing business cases, financial modelling, market entry strategies and assessing growth and m&a opportunities. He has worked for a range of corporates and investment funds in the UK, Europe and Middle East. Sam now operates as a key member of the team, helping produce business models and financial forecasts.
Barry Burles, Non-Executive Director
Barry has developed many medical diagnostic and imaging companies from an early stage. He brings experience to the team and provides mentorship and introductions to move this exciting company forward. He was the Group Executive for Corporate Strategy and Research at Dalgety plc, the largest food and agriscience company in the UK. He was invited to work for the NHS Innovation Health and Wealth initiative, encouraging the Hospital Trusts and Clinical Commissioning Groups to adopt bolder approaches to innovation. He is ideally placed to guide this passionate team to business success.
Richard Allan, Scientific Advisory Board Member
Richard Allan is a qualified tropical parasitologist and has 29 years’ experience as a public health manager. Following four years in primary health care development for Zaire through the mid-1980s he then spent four years in malaria treatment research with Oxford University and the Medical Research Council with programmes in Gambia and Sierra Leone. Since the start of the Rwanda crisis in 1994 Richard has dedicated his efforts to developing disease control initiatives in conflict-based emergencies and natural disasters working with OXFAM,
Richard was the Roll Back Malaria coordinator for complex emergencies, with the Global Secretariat (early 2000 to late 2002) at the World Health Organisation.
Professor Anne Ferguson-Smith, Scientific Advisor
Anne Ferguson-Smith is Professor of Genetics and the head of the Genetics Department at the University of Cambridge. She received her Ph.D. from the Department of Biology at Yale University. For the past two decades, her team has studied genomic imprinting in development and disease and the epigenetic control of genome function in a wider context. She is a Wellcome Senior Investigator, elected member of EMBO and a Fellow of the Academy of Medical Sciences. Anne has a fantastic academic reputation; as such, she is ideally placed to assess the quality of the technology and advise the scientific progression of the company.